Condition: Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) · Sponsor: Pharvaris Netherlands B.V.
This is a Phase 3, multicenter, 3-part study, with 2 randomized, double-blind, placebo-controlled parts and an open-label extension part, to evaluate the efficacy and safety of orally administered deucrictibant XR tablet for prophylaxis, and deucrictibant IR capsule for on-demand treatment of angioedema attacks in adult participants aged ≥ 18 years with AAE-C1INH.
This description comes directly from the study's public registry record.
Pharvaris Clinical Team · 0031-712-036-410 · clinicaltrials@pharvaris.com
Always discuss trial participation with your own doctor first.
| Study Site | San Diego, California, United States | Recruiting |
| Study Site | Walnut Creek, California, United States | Recruiting |
| Study Site | St Louis, Missouri, United States | Recruiting |
| Study Site | Hershey, Pennsylvania, United States | Recruiting |
| Study Site | Clayton, Australia | Recruiting |
| Study Site | Vienna, Austria | Recruiting |
| Study Site | Sofia, Bulgaria | Recruiting |
| Study Site | Edmonton, Canada | Recruiting |
| Study Site | Grenoble, France | Recruiting |
| Study Site | Lille, France | Recruiting |
| Study Site | Paris, France | Recruiting |
| Study Site | Berlin, Germany | Recruiting |
+ 20 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07266805